Edition:
United States

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

10.73USD
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
$10.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,680
52-wk High
$17.11
52-wk Low
$7.85

Chart for

About

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It... (more)

Overall

Beta: -0.41
Market Cap(Mil.): $362.87
Shares Outstanding(Mil.): 35.09
Dividend: --
Yield (%): --

Financials

  SVRA.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -1.86 -- --
ROI: -47.85 1.96 12.83
ROE: -67.16 1.12 14.95

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 09 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $43.93 +0.81
Johnson & Johnson (JNJ.N) $136.56 +2.61
Roche Holding Ltd. (ROG.S) CHF241.10 +0.55
Roche Holding Ltd. (RO.S) CHF241.20 +0.20
Sanofi SA (SASY.PA) €76.93 +0.52
GlaxoSmithKline plc (GSK.L) 1,492.72 +6.72

Earnings vs. Estimates